These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467 [TBL] [Abstract][Full Text] [Related]
7. Diffuse aggressive lymphoma. Fisher RI; Miller TP; O'Connor OA Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685 [TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation. Aurer I Curr Opin Oncol; 2019 Sep; 31(5):374-379. PubMed ID: 31233483 [TBL] [Abstract][Full Text] [Related]
9. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W; Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739 [TBL] [Abstract][Full Text] [Related]
10. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772 [TBL] [Abstract][Full Text] [Related]
11. Treatment of older patients with mantle-cell lymphoma. Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532 [TBL] [Abstract][Full Text] [Related]
12. What is the optimal initial management of the older MCL patient? Kluin-Nelemans JC; Doorduijn JK Best Pract Res Clin Haematol; 2018 Mar; 31(1):99-104. PubMed ID: 29452672 [TBL] [Abstract][Full Text] [Related]
13. [Treatment for mantle cell lymphoma]. Izutsu K Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876 [TBL] [Abstract][Full Text] [Related]
15. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis. Sheng Z; Wang L Eur J Haematol; 2023 Jun; 110(6):602-607. PubMed ID: 36919283 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567 [TBL] [Abstract][Full Text] [Related]
17. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654 [TBL] [Abstract][Full Text] [Related]
18. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. van Keep M; Gairy K; Seshagiri D; Thilakarathne P; Lee D BMC Cancer; 2016 Aug; 16(1):598. PubMed ID: 27488675 [TBL] [Abstract][Full Text] [Related]
20. Transplantation for mantle cell lymphoma: is it the right thing to do? Williams ME Hematology Am Soc Hematol Educ Program; 2013; 2013():568-74. PubMed ID: 24319233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]